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However, this displacement was larger for ventral seeds 
compared to dorsal seeds (see Fig. 1): 4.4±3.1mm versus 
1.7±2.6mm (p<0.001). Of the ventral seeds, cranial seeds 
showed larger displacements than caudal seeds: 5.3±3.1mm 
versus 3.5±3.1mm (p<0.001). 
 
 
Conclusions: Due to prostate volume changes and seed 
displacements after the seed implantation, a reliable 
quantitative assessment of dose-volume parameters for the 
prostate cannot be made at the end of the implantation 
procedure at the OR. A qualitative determination of possible 
cold spots, however, can be made if a potential displacement 
of ventral seed strands in caudal direction is considered.  
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Purpose/Objective: For low (LR)- and intermediate-risk (IR) 
prostate cancer, I-125 seed implant is a highly successful 
treatment modality. However, a small proportion of patients 
show tumor recurrence at some point. Salvage options 
depend on the location of tumor progression. With multi-
parametric MRI and Choline PET, patterns of failure can be 
established. The purpose of this study was therefore to 
identify the location and timing of tumor progression after 
brachytherapy.  
Materials and Methods: Between January 2003 and January 
2011, 328 patients with Gleason ≤7, PSA <20, clinical stage 
T1-T2 and a maximum prostate volume of 60 cc, were 
implanted with I-125 seeds (145 Gy). Date of progression was 
scored at either increase of PSA >2 µg/L above nadir, or 
established recurrence by biopsy and/or imaging, whichever 
was first. A PSA bounce (>2 µg/L increase) with spontaneous 
recovery was not scored as progression. Diagnostic 
procedures (including bone scan, multi-parametric MRI, 
Choline/PET CT, biopsies) were performed in most cases as a 
part of routine follow-up after rising PSA levels, determining 
the location(s) of first relapse. Cumulative incidences were 
estimated using Kaplan-Meier analysis. 
Results: 
 
At a median follow-up of 4.9 years (range 0.3 – 10.4), 5-year 
freedom from failure was 92 % for LR (n=214) and 88 % for IR 
(n=114). Six patients showed a PSA bounce>2 µg/L increase. 
Tumor Relapse was scored in 30 patients; in 4 cases follow-up 
imaging was lacking due to severe comorbidity or a wait and 
see policy. The first relapse location(s) are summarized in Fig 
1 (n=26). Local failure within the gland as (part of) a first 
event occurred in 46 % of the identified failures (12/26) with 
an estimated cumulative 5y incidence of 3.9 % in LR and 3.5 
% in IR patients (Log Rank p=0.8). Local failure in the 
prostate only (all pathology confirmed) occurred in 7 cases 
after a median follow-up of 4.3y (range 1.5 – 7.0) and a 
median PSA nadir of 0.6 µg/L; in 5 cases salvage 
prostatectomy was performed afterwards. Increased uptake 
in the seminal vesicles on follow-up Choline/PET CT (n=6) 
was observed 2 to 6y post-implantation (n=1 pathology 
confirmed). Patients who were diagnosed with distant failure 
as first site (n=5) had early relapses within 2 years and a high 
nadir (1.9 – 13.9 µg/L). Cumulative 5y incidence of failures 
occurring completely outside the gland (n=14) was 3.5 % for 
LR and 6.2 % for IR patients, which was a non-significant 
difference (p=0.15). 
Conclusions: Using multi-parametric MRI and Choline/PET 
CT, patterns of failure after brachytherapy were identified. 
Options for salvage treatment could be adapted accordingly, 
improving patient care. For solitary recurrences a local 
salvage treatment, such as prostatectomy, may be effective. 
The cases of early tumor progression completely outside the 
prostate gland, suggest that pre-treatment screening with 
MRI may improve patient selection and outcome for 
brachytherapy.  
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Purpose/Objective: To demonstrate the application of a 
biologically based inverse optimization algorithm for low dose 
rate (LDR) prostate focal brachytherapy treatment planning.  
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Materials and Methods: The treatment plans for ten patients 
treated with a conventional approach to prostate LDR 
brachytherapy (145 Gy to entire prostate) were compared 
with plans for the same patients created with a biologically 
based inverse optimization planning process. To demonstrate 
functionality of the model, the biological optimizer applied a 
non-uniform distribution of tumor cell density through the 
prostate based on known and expected locations of tumor. 
Using an iterative local search approach, the algorithm 
determined the optimal needle and seed placement to 
achieve the target TCP value whilst constraining urethral 
doses. A range of optimization objectives were considered 
based on maximizing the TCP and minimizing dose to the 
urethra and the volume of tissue posterior to the prostate. 
For each clinical plan, 3 focal plans were generated based on 
3 different planning approaches. The robustness of the plans 
was tested in the presence of random displacement of seeds.  
Results: Depending on the planning approach, the volume of 
the urethra receiving 125% of the conventional dose 
prescription (145 Gy) was reduced on average from 64% (SD 
17%) for the clinical plans to below 13% for the focal plans 
whilst maintaining high values of TCP through use of a 
biological optimization approach. The average number of 
planned seeds was reduced from 85 to less than 74 in all 3 
focal planning approaches. The robustness of the plans was 
not inferior to the conventional plans when considering 
clinically realistic seed displacements. Clinically, this 
planning approach will use a combination of in-vivo multi-
parametric MRI imaging (mp-MRI) data and biopsy data to 
populate the radiobiological model with patient specific 
tumor characteristics. Early work demonstrates that T2w, 
DCE, DWI and BOLD imaging are capable of providing a voxel 
map incorporating tumor location, tumor cell density, cell 
proliferation and hypoxia information. Future work is focused 
on modeling uncertainties in mp-MRI data and incorporating a 
statistical model to generate clinically robust focal 
brachytherapy plans using LDR or high dose rate 
brachytherapy. 
Conclusions: We have demonstrated, using a combination of 
clinical and synthesized data, that a biologically based 
inverse planning approach to LDR treatments has the 
potential to maintain high rates of tumor control whilst 
minimizing dose to healthy tissue. The software is designed 
to use mp-MRI and biopsy data to inform the biological 
model.  
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Purpose/Objective: Organ-confined prostate cancer 
recurrences after primary radiotherapy can be curatively 
treated with salvage Iodine-125 brachytherapy (I-125 BT). 
Options include a complete re-implantation or focal salvage 
directed only at the recurrent tumor area. This study 
assesses the differences in rectal dosimetry between these 
two approaches and provides dose constraints to reduce late 
severe gastro-intestinal (GI) toxicity (>90 days after 
implantation). 
Materials and Methods: Intraoperative dosimetry for 20 focal 
salvage (FS) and 28 total salvage (TS) BT patients was 
evaluated. Patients were treated from December 2001 until 
October 2012. The dosimetry recommendations for primary 
BT according to the American brachytherapy society (ABS) 
and the European Society for Radiotherapy and Oncology 
(ESTRO) were used. GI toxicity was evaluated using the 
CTCAE version 4. Differences between dosimetry variables 
were analyzed with a Mann-Whitney U test. Receiver 
operating characteristic (ROC)-analysis was used for 
dosimetry cutoff values to prevent late severe (≥ grade 2) GI 
toxicity.  
Results: FS I-125 BT leads to a significant dose reduction in 
all analyzed parameters for the rectum compared to TS I-125 
BT. Median reductions in D0.1cc, D1cc, D2cc and V100 were 
38Gy (p=0.002), 46Gy (p<0.0001), 46Gy (p<0.0001) and 
0.41cc (p=0.0001) for FS patients compared to TS patients 
(table 1). No late severe (≥ grade 2) GI toxicity was observed 
in the FS group. TS patients with severe GI toxicity (41%, 
n=11) showed significantly higher doses to the rectum than 
TS patients without GI toxicity (59%, n=16). The median 
difference in the D0.1cc, D1cc, D2cc and V100 were 29 Gy 
(p=0.0009), 17 Gy (p=0.001), 28 Gy (p=0.0007) and 0.45cc 
(p=0.001) between TS patients with and without late severe 
GI toxicity (figure 1). With ROC-analysis, restrictions for the 
D0.1cc, D1cc, D2cc and V100 are <160Gy (AUC 0.881, 95%CI: 
0.755-1.000), <119Gy (AUC 0.869, 95%CI: 0.735-1.000), 
<102Gy (AUC 0.892, 95%CI: 0.772-1.000) and < 0.38cc (AUC 
0.875, 95%CI: 0.747-1.000), respectively.  
Conclusions: FS I-125 BT reduces the dose to the rectum 
significantly compared to TS. Centers performing TS I-125 BT 
have to be aware of the risk of cumulative rectal dose and 
subsequent severe GI toxicity. Based on these findings, the 
rectal D0.1cc, D1cc, D2cc and V100 should remain below 
160Gy, 119Gy, 102Gy and 0.38cc. 
 
 
   
 
 
Table 1: dosimetry differences between the focal and total salvage treatment 
plans 
Organ Variable TS 
group 
(n=28) 
FS group 
(n=20) 
Median 
reduction 
Recommendatio
ns* 
p-value for 
difference 
Rectum D0.1cc, 
Gy 
166 (90 –
289) 
128 (90 –
181) 
38 Gy 
< 200 Gy 0.002 
D1cc, Gy 130 (59 –
185) 
84 (61 –
111) 
46 Gy 
NA <0.0001 
D2cc, Gy 111 (46 –
145) 
65 (38 –
88) 
46 Gy 
≤ 100% (=145 Gy) <0.0001 
 V100, cc 0.43 (0 –
2.02)  
0.02 (0 –
0.39) 
0.41cc 
<1 cc 0.0001 
 V150, cc 0.01 (0 –
0.59) 
0 (0 –
0.04) 
0.01cc 
NA 0.037 
Abbreviations: FS=focal salvage; TS-=total salvage; Gy=Gray. Medians and their 
corresponding ranges are depicted.  
*The recommendations are from the American Brachytherapy Society (ABS) 
and European Society for Radiotherapy and Oncology (ESTRO). 
